e-ISSN: Pending
Negative / Null Result ReportOpen accessTherapeutics. Pharmacology

The effect of adding ivermectin to the standard COVID-19 treatment in intubated patients

Reza Baghbanian; Mohsen Savaie; Farhad Soltani; Mahbobeh Rashidi; Mehrdad Dargahi MalAmir; Fereshteh Amiri; Nima Bakhtiari · 2023 · Journal of Nephropharmacology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Introduction: Effective antiviral medications with minimal side effects has received scholarly attention since the start of the COVID-19 pandemic. Ivermectin, a long-time anti-parasitic drug, has been proven through laboratory tests to have anti-COVID-19 effects. Objectives: This study investigated the effects of inclusion of ivermectin to the standard treatment of mechanically ventilated patients. Patients and Methods: This study is a double-blinded, randomized, placebo-controlled clinical trial that was conducted on COVID-19 patients, in Ahvaz, Iran, from March 2020 to September 2021. Intuba

Abstract by Reza Baghbanian; Mohsen Savaie; Farhad Soltani; Mahbobeh Rashidi; Mehrdad Dargahi MalAmir; Fereshteh Amiri; Nima Bakhtiari, Journal of Nephropharmacology (2023) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.34172/npj.2023.10589